ATOS
Price
$0.75
Change
-$0.04 (-5.06%)
Updated
Aug 19, 04:59 PM (EDT)
Capitalization
96.88M
89 days until earnings call
ZIVO
Price
$18.49
Change
+$0.24 (+1.32%)
Updated
Aug 18 closing price
Capitalization
68.8M
Interact to see
Advertisement

ATOS vs ZIVO

Header iconATOS vs ZIVO Comparison
Open Charts ATOS vs ZIVOBanner chart's image
Atossa Therapeutics
Price$0.75
Change-$0.04 (-5.06%)
Volume$1.45K
Capitalization96.88M
Zivo Bioscience
Price$18.49
Change+$0.24 (+1.32%)
Volume$1.23K
Capitalization68.8M
ATOS vs ZIVO Comparison Chart in %
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZIVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. ZIVO commentary
Aug 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and ZIVO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 20, 2025
Stock price -- (ATOS: $0.75 vs. ZIVO: $18.04)
Brand notoriety: ATOS and ZIVO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 55% vs. ZIVO: 183%
Market capitalization -- ATOS: $96.88M vs. ZIVO: $68.8M
ATOS [@Biotechnology] is valued at $96.88M. ZIVO’s [@Biotechnology] market capitalization is $68.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.19B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileZIVO’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • ZIVO’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATOS and ZIVO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 3 TA indicator(s) are bullish while ZIVO’s TA Score has 5 bullish TA indicator(s).

  • ATOS’s TA Score: 3 bullish, 5 bearish.
  • ZIVO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ZIVO is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а -2.95% price change this week, while ZIVO (@Biotechnology) price change was +0.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.66%. For the same industry, the average monthly price growth was +26.04%, and the average quarterly price growth was +19.36%.

Reported Earning Dates

ATOS is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+2.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($96.9M) has a higher market cap than ZIVO($68.8M). ZIVO YTD gains are higher at: -16.093 vs. ATOS (-20.559). ZIVO has higher annual earnings (EBITDA): -9.7M vs. ATOS (-29.97M). ATOS has more cash in the bank: 57.9M vs. ZIVO (9.82K). ATOS has less debt than ZIVO: ATOS (0) vs ZIVO (779K). ZIVO has higher revenues than ATOS: ZIVO (175K) vs ATOS (0).
ATOSZIVOATOS / ZIVO
Capitalization96.9M68.8M141%
EBITDA-29.97M-9.7M309%
Gain YTD-20.559-16.093128%
P/E RatioN/AN/A-
Revenue0175K-
Total Cash57.9M9.82K589,433%
Total Debt0779K-
FUNDAMENTALS RATINGS
ATOS vs ZIVO: Fundamental Ratings
ATOS
ZIVO
OUTLOOK RATING
1..100
7832
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8538
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (24) in the Medical Specialties industry is somewhat better than the same rating for ZIVO (80) in the null industry. This means that ATOS’s stock grew somewhat faster than ZIVO’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ZIVO (100) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

ATOS's SMR Rating (97) in the Medical Specialties industry is in the same range as ZIVO (100) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

ZIVO's Price Growth Rating (38) in the null industry is somewhat better than the same rating for ATOS (85) in the Medical Specialties industry. This means that ZIVO’s stock grew somewhat faster than ATOS’s over the last 12 months.

ZIVO's P/E Growth Rating (100) in the null industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that ZIVO’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSZIVO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 23 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZIVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
THURF0.030.01
+25.00%
Thunderstruck Resources Ltd
JRONY49.220.45
+0.92%
Jeronimo Martins, SGPS, SA
EBRPF17.76N/A
N/A
Ebro Foods SA
SRGXF0.11N/A
-0.16%
Surge Copper Corp.
PROBF1.65-0.09
-4.95%
PROBE GOLD INC

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-5.06%
AXON - ATOS
42%
Loosely correlated
-4.21%
RGNX - ATOS
42%
Loosely correlated
-7.81%
PDSB - ATOS
42%
Loosely correlated
-5.65%
NRIX - ATOS
41%
Loosely correlated
-3.58%
NTLA - ATOS
41%
Loosely correlated
-4.10%
More

ZIVO and

Correlation & Price change

A.I.dvisor tells us that ZIVO and APLM have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZIVO and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZIVO
1D Price
Change %
ZIVO100%
-2.43%
APLM - ZIVO
28%
Poorly correlated
-3.51%
LGVN - ZIVO
24%
Poorly correlated
+2.32%
MDXXF - ZIVO
24%
Poorly correlated
N/A
AKRO - ZIVO
23%
Poorly correlated
-2.04%
ATOS - ZIVO
23%
Poorly correlated
-5.06%
More